MRNA vs PATH · rev $1.94B vs P/E 19, rev $1.61B
Moderna Inc (MRNA) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stephane Bancel.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported MRNA revenue for 2025-12-31 was $1.94B. Net income was -$2.82B. Revenue was down 39.9% from 2024-12-31 to 2025-12-31. MRNA currently screens at market cap $24.52B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
MRNA currently screens at market cap $24.52B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the MRNA and PATH stock pages for the full models.
Not investment advice.